Innovent Biologics, Inc.
IVBXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $9 | $6 | $5 | $4 |
| % Growth | 51.8% | 36.2% | 6.7% | – |
| Cost of Goods Sold | $2 | $2 | $1 | $1 |
| Gross Profit | $8 | $4 | $4 | $4 |
| % Margin | 84% | 70.9% | 79.6% | 86.6% |
| R&D Expenses | $3 | $2 | $3 | $2 |
| G&A Expenses | $1 | $1 | $1 | $1 |
| SG&A Expenses | $5 | $4 | $3 | $4 |
| Sales & Mktg Exp. | $4 | $3 | $3 | $3 |
| Other Operating Expenses | -$0 | $0 | -$0 | -$0 |
| Operating Expenses | $8 | $6 | $6 | $6 |
| Operating Income | -$1 | -$2 | -$3 | -$3 |
| % Margin | -8% | -27.1% | -68.5% | -63.3% |
| Other Income/Exp. Net | $0 | $1 | $1 | $0 |
| Pre-Tax Income | -$0 | -$1 | -$2 | -$3 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$0 | -$1 | -$2 | -$3 |
| % Margin | -1% | -16.6% | -47.8% | -63.9% |
| EPS | -0.058 | -0.66 | -1.46 | -1.88 |
| % Growth | 91.2% | 54.8% | 22.3% | – |
| EPS Diluted | -0.056 | -0.66 | -1.46 | -1.88 |
| Weighted Avg Shares Out | 2 | 2 | 1 | 1 |
| Weighted Avg Shares Out Dil | 2 | 2 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$1 | -$2 | -$2 |
| % Margin | -5.1% | -10.6% | -38.4% | -55.6% |